Compare TNON & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNON | SNOA |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 6.1M |
| IPO Year | N/A | 2006 |
| Metric | TNON | SNOA |
|---|---|---|
| Price | $0.78 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 73.8K | ★ 370.7K |
| Earning Date | 05-05-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,288,000.00 |
| Revenue This Year | $65.95 | $23.00 |
| Revenue Next Year | $50.54 | $24.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 12.19 |
| 52 Week Low | $0.64 | $0.85 |
| 52 Week High | $2.48 | $6.92 |
| Indicator | TNON | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 31.31 |
| Support Level | $0.76 | $0.85 |
| Resistance Level | $0.82 | $3.88 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 48.24 | 20.39 |
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.